Sign In
Buy NTLA
$12.02
+0.0800 (+0.670%)
At Close: Aug 10, 2026
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
07:30am, Friday, 01'st Aug 2025
CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based thera
Bragar Eagel & Squire, P.C. Litigation Attorneys Encourage Investors Who Suffered Losses In Intellia (NTLA) To Contact Him Directly To Discuss Their Options
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates
07:30am, Thursday, 31'st Jul 2025
CAMBRIDGE, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based thera
3 Genomics Stocks Worth Adding to Your Portfolio in 2025
10:45am, Wednesday, 30'th Jul 2025
An updated edition of the June 27, 2025, article.
With Intellia Therapeutics, Human Patience Beat Hot-Take Trading: Still At 'Buy'
08:00am, Friday, 18'th Jul 2025
Investors often react fast to news. We see it with earnings announcements. And in biotech/pharma, we see it in response to news about drug trials. We saw that in spades on 5/29/25 for gene editor Inte
Goldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlook
04:27pm, Tuesday, 15'th Jul 2025
In a recent market update, Goldman Sachs raised its year-end forecast for the S&P 500 (SPX) to 6,900 by year-end, up from a previous ceiling of 6,500, and flagged three stocks investors should have on
Move Over, Magnificent 7: The Frontier 7 Will Redefine Our Future
10:54am, Thursday, 10'th Jul 2025
Key Points in This Article: The Magnificent 7 transformed markets through AI and digital ecosystems, turning a once-pejorative label into a celebrated symbol of innovation and growth.
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Monday, 07'th Jul 2025
CAMBRIDGE, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based thera
Intellia Gains 29.8% in a Month: How Should You Play the Stock?
10:50am, Monday, 07'th Jul 2025
NTLA stock surges 29.8% in a month, driven by gene therapy pipeline progress and growing investor attention.
CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?
11:05am, Wednesday, 25'th Jun 2025
CRSP edges ahead of NTLA with the only approved CRISPR therapy, stronger pipeline breadth and recent stock gains.
CAMBRIDGE, Mass., June 15, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based thera
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Thursday, 05'th Jun 2025
CAMBRIDGE, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based thera
How Much Upside is Left in Intellia Therapeutics (NTLA)? Wall Street Analysts Think 398.31%
11:01am, Wednesday, 04'th Jun 2025
The consensus price target hints at a 398.3% upside potential for Intellia Therapeutics (NTLA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ear
NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study
11:21am, Friday, 30'th May 2025
Intellia stock tanks after a patient in its phase III study evaluating gene therapy candidate nex-z in ATTR-CM experiences serious liver enzyme elevation.
Intellia Therapeutics' Rare Heart Disease Candidate Reports Liver Enzyme Spike In Phase 3 Trial, But Stays On Course
11:25am, Thursday, 29'th May 2025
Intellia Therapeutics Inc NTLA said on Wednesday that a single, recent, asymptomatic patient has had grade 4 (severe) liver transaminase elevations (liver enzymes) based on laboratory tests in its Pha
